Clinical Trial Update: Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks [Phase 3]

View source ↗

Summary

Phase 3 trial assessing adding Fluticasone Propionate/Salmeterol to umeclidinium for COPD over 12 weeks; results completed with posted data in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone propionate/salmeterol (fluticasone propionate/salmeterol)
• Umeclidinium bromide (umeclidinium bromide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-04-16